ArticleMolecular oncology2018
Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
Article in Molecular oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2023Pooled it
- Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Pooled it
- Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.BMC cancer · 2019Pooled it
- Detection ofBiomolecules · 2021Trial
- Biological basis and clinical translation prospects of circulating cell-free DNA in precision management of breast cancer (Review).Oncology letters · 2026Review
- Biomarker testing in advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer: expert recommendations.Therapeutic advances in medical oncology · 2026Review
- [Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 5th Hungarian Consensus Conference on Breast Cancer].Magyar onkologia · 2025Article
- Unraveling the Potential of ctDNA in Precision Medicine for Breast Cancer.Molecular diagnosis & therapy · 2025Review
- The impact of liquid biopsy in breast cancer: Redefining the landscape of non-invasive precision oncology.The journal of liquid biopsy · 2025Review
- PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.Cancer medicine · 2024Article
- Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques.Current oncology (Toronto, Ont.) · 2024Review
- Review
- Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer.NPJ breast cancer · 2023Review
- A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer.International journal of molecular sciences · 2023Review
- Review
- "Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?"Breast cancer (Dove Medical Press) · 2023Review
- Association between PIK3CA Mutations in Blood and Tumor-Infiltrating Lymphocytes in Peruvian Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer.International journal of molecular sciences · 2022Review
- Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.Journal of translational medicine · 2022Article
- The History and Future of Basic and Translational Cell-Free DNA Research at a Glance.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsies focusing on the analysis of cell-free circulating tumor DNA (ctDNA) may have important clinical implications for personalized medicine, including early detection of cancer, therapeutic guidance, and monitoring of recurrence. Mutations in the oncogene, PIK3CA, are frequently observed in breast cancer and have been suggested as a predictive biomarker for PI3K-selective inhibitor treatment. In this study, we analyzed the presence of PIK3CA mutations in formalin-fixed, paraffin-embedded, metastatic tissue and corresponding ctDNA from serum of patients with advanced breast cancer using a highly sensitive, optimized droplet digital PCR (ddPCR) assay. We found 83% of patients with PIK3CA mutation in the metastatic tumor tissue also had detectable PIK3CA mutations in serum ctDNA. Patients lacking the PIK3CA mutation in corresponding serum ctDNA all had nonvisceral metastatic disease. Four patients with detectable PIK3CA-mutated ctDNA were followed with an additional serum sample during oncological treatment. In all cases, changes in PIK3CA ctDNA level correlated with treatment response. Our results showed high concordance between detection of PIK3CA mutations in tumor tissue and in corresponding serum ctDNA and suggest that serum samples from patients with advanced breast cancer and ddPCR may be used for PIK3CA mutation status assessment to complement imaging techniques as an early marker of treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.